Scarica l'app Stockscreener
8.55
0.12%
-0.010
Dopo l'orario di chiusura:
8.55
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché NEO Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$8.56
Aprire:
$8.49
Volume 24 ore:
1.13M
Relative Volume:
0.62
Capitalizzazione di mercato:
$1.11B
Reddito:
$727.33M
Utile/perdita netta:
$-108.03M
Rapporto P/E:
-10.13
EPS:
-0.844
Flusso di cassa netto:
$-21.78M
1 W Prestazione:
-6.04%
1M Prestazione:
-25.33%
6M Prestazione:
+2.52%
1 anno Prestazione:
-21.42%
Intervallo 1D:
$8.43
$8.65
Intervallo di 1 settimana:
$8.43
$9.38
Portata 52W:
$4.72
$13.74
Neogenomics Inc Stock (NEO) Company Profile
Nome
Neogenomics Inc
Settore
Industria
Telefono
(239) 768-0600
Indirizzo
9490 NEOGENOMICS WAY, FORT MYERS, FL
Compare NEO vs TMO, DHR, IDXX, A, WAT
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NEO
Neogenomics Inc
|
8.55 | 1.11B | 727.33M | -108.03M | -21.78M | -0.844 |
|
TMO
Thermo Fisher Scientific Inc
|
495.72 | 185.77B | 44.56B | 6.72B | 6.29B | 17.74 |
|
DHR
Danaher Corp
|
195.06 | 138.05B | 24.57B | 3.60B | 5.26B | 5.051 |
|
IDXX
Idexx Laboratories Inc
|
600.52 | 47.68B | 4.30B | 1.06B | 1.04B | 13.08 |
|
A
Agilent Technologies Inc
|
115.42 | 32.62B | 7.07B | 1.29B | 993.00M | 4.5355 |
|
WAT
Waters Corp
|
297.54 | 29.39B | 3.17B | 642.63M | 516.49M | 10.77 |
Neogenomics Inc Stock (NEO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-30 | Downgrade | BTIG Research | Buy → Neutral |
| 2025-07-29 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2025-05-15 | Iniziato | Guggenheim | Neutral |
| 2025-04-30 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2025-01-13 | Downgrade | The Benchmark Company | Buy → Hold |
| 2024-12-10 | Iniziato | Jefferies | Buy |
| 2024-05-01 | Ripresa | Craig Hallum | Buy |
| 2023-12-29 | Reiterato | BTIG Research | Buy |
| 2023-08-21 | Aggiornamento | Stephens | Equal-Weight → Overweight |
| 2023-05-16 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2023-05-09 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2023-02-24 | Aggiornamento | The Benchmark Company | Hold → Buy |
| 2023-02-01 | Aggiornamento | Needham | Hold → Buy |
| 2022-08-26 | Downgrade | The Benchmark Company | Buy → Hold |
| 2022-08-22 | Downgrade | Needham | Buy → Hold |
| 2022-06-03 | Iniziato | Piper Sandler | Overweight |
| 2022-03-29 | Downgrade | BofA Securities | Buy → Neutral |
| 2022-03-29 | Downgrade | Stephens | Overweight → Equal-Weight |
| 2022-01-18 | Ripresa | Stephens | Overweight |
| 2021-12-16 | Iniziato | Cowen | Outperform |
| 2021-11-05 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-10-14 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2021-06-03 | Iniziato | Goldman | Buy |
| 2021-02-25 | Ripresa | Needham | Buy |
| 2021-02-25 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2021-01-28 | Iniziato | Truist | Buy |
| 2020-12-11 | Ripresa | BTIG Research | Buy |
| 2020-10-28 | Reiterato | Needham | Buy |
| 2020-09-09 | Iniziato | Morgan Stanley | Overweight |
| 2020-08-28 | Iniziato | Guggenheim | Buy |
| 2020-07-29 | Reiterato | Needham | Buy |
| 2020-06-25 | Iniziato | BofA/Merrill | Buy |
| 2020-04-21 | Ripresa | Stephens | Overweight |
| 2020-03-02 | Ripresa | Craig Hallum | Buy |
| 2020-02-28 | Aggiornamento | First Analysis Sec | Outperform → Strong Buy |
| 2020-01-23 | Downgrade | First Analysis Sec | Strong Buy → Outperform |
| 2019-10-30 | Reiterato | Needham | Buy |
| 2019-05-01 | Reiterato | Needham | Buy |
| 2019-03-29 | Reiterato | Needham | Buy |
| 2019-01-03 | Iniziato | Needham | Buy |
| 2018-10-24 | Aggiornamento | First Analysis Sec | Outperform → Strong Buy |
| 2018-08-21 | Iniziato | Leerink Partners | Outperform |
| 2018-05-02 | Downgrade | First Analysis Sec | Overweight → Equal-Weight |
| 2017-09-11 | Downgrade | BTIG Research | Buy → Neutral |
| 2017-08-24 | Iniziato | Gabelli & Co | Buy |
| 2016-12-15 | Iniziato | Cantor Fitzgerald | Overweight |
Mostra tutto
Neogenomics Inc Borsa (NEO) Ultime notizie
NeoGenomics at Leerink Conference: Strategic Growth Focus - Investing.com
Investment Recap: Is NeoGenomics Inc gaining market share2026 Volatility Report & Long Hold Capital Preservation Tips - baoquankhu1.vn
Insider Sell: Can NeoGenomics Inc deliver alphaMarket Activity Report & Expert Verified Movement Alerts - baoquankhu1.vn
GW&K Investment Management LLC Cuts Stock Position in NeoGenomics, Inc. $NEO - MarketBeat
Royce & Associates LP Sells 860,000 Shares of NeoGenomics, Inc. $NEO - MarketBeat
Vanguard Group Inc. Has $107.34 Million Stock Position in NeoGenomics, Inc. $NEO - MarketBeat
NeoGenomics, Inc. $NEO Shares Sold by Segall Bryant & Hamill LLC - MarketBeat
NeoGenomics (NEO) accounting chief granted new options and RSUs - Stock Titan
Equity awards expand NeoGenomics (NEO) EVP Olivo’s stock-based pay - Stock Titan
NeoGenomics (NEO) COO receives new stock option and RSU grants - Stock Titan
Major equity grants to NeoGenomics (NEO) CEO Anthony P. Zook - Stock Titan
NeoGenomics at TD Cowen Conference: Strategic Growth Insights By Investing.com - Investing.com Canada
NeoGenomics at TD Cowen Conference: Strategic Growth Insights - Investing.com South Africa
A Look At NeoGenomics (NEO) Valuation After The RaDaR ST Assay Launch - simplywall.st
NeoGenomics Stock Price Drops Below 200-Day Average - National Today
NeoGenomics (NASDAQ:NEO) Stock Price Crosses Below 200-Day Moving AverageHere's What Happened - MarketBeat
NeoGenomics (NEO) CFO Abhishek Jain granted options and RSUs - Stock Titan
Oversold Conditions For NeoGenomics (NEO) - Nasdaq
NEO Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
NEO Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Earnings are out: How did SWFL companies perform? - Naples Daily News
Natera, NeoGenomics Unit End Patent Suit Over Lung Cancer Test - Bloomberg Law News
3 Reasons to Avoid NEO and 1 Stock to Buy Instead - Yahoo Finance
(NEO) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
NeoGenomics Launches RaDaR ST, Expanding Molecular Residual Disease Testing Across Multiple Solid Tu - PharmiWeb.com
NeoGenomics Launches RaDaR ST Molecular Residual Disease Test - marketscreener.com
NeoGenomics, Inc. Launches RaDaR ST, Expanding Molecular Residual Disease Testing Across Multiple Solid Tumor Types - marketscreener.com
NeoGenomics Launches RaDaR ST, Expanding Molecular Residual Disease Testing Across Multiple Solid Tumor Types - The Joplin Globe
NeoGenomics, Inc. Trade Ideas — FWB:NG9 - TradingView
NeoGenomics outlines $793M–$801M 2026 revenue target as RaDaR ST and PanTracer initiatives gain traction - MSN
NeoGenomics (NEO) COO logs RSU vesting and tax share withholding - Stock Titan
Equity moves for NeoGenomics (NASDAQ: NEO) CFO Jeffrey Sherman - Stock Titan
NeoGenomics (NEO) EVP nets new shares from RSU vesting and tax withholding - Stock Titan
NeoGenomics (NEO) CAO converts RSUs to stock and withholds shares for taxes - Stock Titan
NeoGenomics, Inc. Experiences Revision in Its Stock Evaluation Amid Mixed Financial Indicators - Markets Mojo
5 Insightful Analyst Questions From NeoGenomics's Q4 Earnings Call - Finviz
NeoGenomics, Inc. (NEO) Stock Analysis: A 47% Upside Potential in the Healthcare Diagnostics Sector - DirectorsTalk Interviews
5 Insightful Analyst Questions From NeoGenomics’s Q4 Earnings Call - Yahoo Finance
NeoGenomics (NEO) Q4 2025 Earnings Call Transcript - AOL.com
NeoGenomics, Inc. (NASDAQ:NEO) Receives Consensus Rating of "Hold" from Brokerages - MarketBeat
Assessing NeoGenomics (NEO) Valuation After Recent Share Price Weakness - Yahoo Finance
NeoGenomics, Inc. $NEO Shares Bought by White Pine Capital LLC - MarketBeat
NeoGenomics, Inc. $NEO Stock Holdings Lifted by Aberdeen Group plc - MarketBeat
Short Squeeze: What is the PEG ratio of Brookdale Senior Living IncStock Surge & Free Growth Oriented Trading Recommendations - baoquankhu1.vn
After Plunging 22.8% in 4 Weeks, Here's Why the Trend Might Reverse for NeoGenomics (NEO) - Finviz
NeoGenomics to Participate in the 20th Annual Needham Virtual Healthcare Conference - ACCESS Newswire
Why is NeoGenomics Inc. stock going upM&A Rumor & Free High Accuracy Swing Entry Alerts - mfd.ru
UBS Maintains Hold on NeoGenomics, Inc. (NEO) on Feb 18, 2026 - Meyka
Needham & Company LLC Forecasts Strong Price Appreciation for NeoGenomics (NASDAQ:NEO) Stock - Defense World
NeoGenomics Q4 Earnings Call Highlights - Defense World
NeoGenomics Faces High-Stakes Risk as Test Reliability and Diagnostic Errors Threaten Reputation and Legal Exposure - TipRanks
Neogenomics Inc Azioni (NEO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.17%
0.64%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):